Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Thoracic 5Other hematologic neoplasm 4Genitourinary 4Head & Neck 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Locally Advanced Esophageal or GE Junction Cancer 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
gossypol acetic acid × Gastrointestinal × Clear all
NCT00561197 2013-01-04

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Ascenta Therapeutics

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Locally Advanced Esophageal or GE Junction Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡